Nerandomilast (BI 1015550) is an investigational oral drug that selectively inhibits phosphodiesterase 4B, exhibiting antifibrotic and immune-modulating effects. In previous...
pulmonary
LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that...
Billy, Vicky and Betty successfully completed the Pulmonary Rehab Program at RWJUH Hamilton, and celebrated with a cake presented by...
Nerandomilast met its primary end point of absolute change from baseline in forced vital capacity (FVC) vs placebo in the...
Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with...
Research design and participantsOur study included participants from the UK Biobank ( a comprehensive longitudinal cohort study initiated between 2006...
